Xeloda 2000mg

Patients xeloda severe diarrhea should be carefully monitored and given fluid and electrolyte replacement 2000mg they become dehydrated, xeloda 2000mg.

In patients with either metastatic breast or colorectal cancer who received XELODA monotherapy, xeloda median time to first occurrence of grade 2 to 4 diarrhea was 34 days range from 1 to days, xeloda 2000mg. The median duration of grade 3 to 4 diarrhea 2000mg 5 days.

xeloda 500mg

Standard xeloda treatments eg, xeloda 2000mg, loperamide are recommended. Necrotizing enterocolitis typhlitis has been reported. These adverse reactions may be more common in patients with a prior history of coronary artery disease. Dihydropyrimidine Dehydrogenase Deficiency Based on postmarketing reports, patients with certain 2000mg or certain compound 2000mg mutations in the DPD xeloda that result in complete or near complete absence of DPD activity are at increased risk for acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by XELODA e.

Withhold or permanently discontinue XELODA based on clinical assessment of the onset, xeloda 2000mg, duration and severity of the observed toxicities in patients with evidence of acute early-onset or unusually severe toxicity, which may xeloda near complete or total absence of DPD activity. There is insufficient data to recommend a specific dose in patients with partial DPD activity as 2000mg by any specific test.

Dehydration And Renal Failure Dehydration has been observed and may cause acute xeloda failure which can be fatal. Patients with preexisting compromised renal function or who are receiving concomitant XELODA with known nephrotoxic agents are at higher risk. Patients with anorexiaastheniaxeloda 2000mg, xeloda, vomiting or diarrhea may rapidly become dehydrated.

If grade 2 or higher dehydration occurs, XELODA treatment should be immediately interrupted and prednisone 25mg tabs dehydration corrected. Treatment should not be 2000mg until the patient is rehydrated and any precipitating causes have been corrected or controlled.

Patients with mild and moderate renal impairment at baseline should be carefully monitored for adverse 2000mg.

Capecitabine caused embryolethality and teratogenicity in mice and embryolethality in monkeys when administered during organogenesis. If this drug is used during pregnancy, or if a patient becomes pregnant while xeloda XELODA, the patient should be apprised of the potential hazard to the fetus [see Use In Specific Populations]. Hand-and-foot syndrome palmar - plantar erythrodysesthesia or chemotherapy -induced acral erythema is a cutaneous toxicity. Median time to onset was 79 days range from 11 to days with a severity range of grades 1 to 3 for patients receiving XELODA xeloda in the metastatic setting.

Grade 2000mg is characterized by any of the following: If grade 2 or 3 hand-and-foot syndrome occurs, administration of XELODA should be interrupted until the event resolves xeloda decreases in intensity to grade 1. Of patients who had hepatic metastases at baseline and patients without hepatic metastases at baseline, grade 3 or 4 hyperbilirubinemia occurred in Of the patients with grade 3 or 4 hyperbilirubinemia, The majority of these patients, In the patients treated with XELODA as first-line therapy for metastatic colorectal cancer, the incidence of grade 3 or 4 hyperbilirubinemia was similar to the overall clinical trial 2000mg database of XELODA monotherapy.

Of the colorectal cancer patients with grade 3 or 4 hyperbilirubinemia, 49 patients had grade 3 or 4 hyperbilirubinemia as their last measured value, of which 46 had liver metastases at baseline. If 2000mg laboratory assessments during a treatment cycle show grade 3 or 4 hematologic toxicity, xeloda 2000mg, treatment with XELODA should be interrupted.

Hepatic Insufficiency Patients with mild to moderate hepatic dysfunction due to liver metastases should be carefully monitored when XELODA is administered. As described below, patients taking XELODA should be informed of the need to interrupt treatment and to call their physician immediately if moderate or severe toxicity occurs. Dihydropyrimidine Dehydrogenase Deficiency Patients should be advised to notify their healthcare provider if they have a known DPD deficiency.

Advise patients if they have complete or near complete absence of DPD activity they are at an increased risk of acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by XELODA e. Dehydration Patients experiencing grade 2 or higher dehydration should be instructed to stop taking XELODA immediately and the dehydration corrected. Nausea Patients experiencing grade 2 nausea food intake significantly decreased but able to eat intermittently or greater should be instructed to stop taking XELODA immediately, xeloda 2000mg.

Xeloda 150mg & 500 mg Film-coated Tablets

Initiation of symptomatic treatment is recommended. Vomiting Patients experiencing grade 2 vomiting 2 to 2000mg episodes in a hour period or xeloda should be instructed to stop taking XELODA immediately, xeloda 2000mg. Stomatitis Patients experiencing grade 2 stomatitis painful erythema, edema or ulcers of xeloda mouth or tongue, but able to eat or greater should be instructed to stop taking XELODA immediately and to call their physician.

Fever And Neutropenia Patients 2000mg develop a fever of xeloda Capecitabine was clastogenic 2000mg vitro to human peripheral blood lymphocytes but not clastogenic in vivo to mouse bone marrow micronucleus test. Fluorouracil causes mutations in bacteria and yeast.

Fluorouracil also causes chromosomal abnormalities in the mouse micronucleus xeloda in vivo, xeloda 2000mg. In mice that became pregnant, xeloda 2000mg, no fetuses survived this dose, xeloda 2000mg. The disturbance in estrus was reversible.

In males, this dose caused degenerative changes in the testes, including decreases in the number 2000mg spermatocytes and spermatids. Malformations in mice included cleft palateanophthalmiaxeloda 2000mg, microphthalmiaxelodapolydactylyxeloda 2000mg, syndactylykinky tail and dilation of cerebral ventricles. If this drug is used during pregnancy, or if a patient becomes pregnant while receiving 2000mg, the patient should be apprised of the potential hazard to the fetus.

Nursing Mothers Lactating mice given a single oral dose xeloda capecitabine excreted significant amounts of capecitabine metabolites into xeloda milk. It is not known whether this drug is excreted in human milk.

Because many drugs xeloda excreted in human milk and because of the potential for serious xeloda reactions in nursing infants from capecitabine, xeloda 2000mg, a decision should 2000mg made whether to discontinue 2000mg or to discontinue the drug, taking into account the importance 2000mg the drug to the mother, xeloda 2000mg. No clinical benefit was demonstrated in two single arm trials in pediatric patients with newly diagnosed brainstem gliomas and high grade gliomas.

In both trials, pediatric xeloda received 2000mg investigational pediatric formulation of capecitabine concomitantly with and following completion of radiation therapy total dose of cGy in cGy fractions. The first trial was conducted in 22 pediatric patients median age 8 years, xeloda 2000mg, range years with newly xeloda non-disseminated intrinsic 2000mg brainstem gliomas and xeloda grade gliomas. The major 2000mg limiting toxicities 2000mg palmar-plantar erythrodysesthesia and alanine aminotransferase ALT elevation.

The second trial was conducted in 34 additional pediatric patients with newly diagnosed nondisseminated intrinsic diffuse brainstem gliomas median age 7 years, range years xeloda 10 pediatric patients who received the MTD of capecitabine in the dose-finding trial and met the eligibility criteria for this trial, xeloda 2000mg.

There was no improvement xeloda one-year progression-free survival rate and one-year overall survival rate in 2000mg patients with newly diagnosed intrinsic brainstem gliomas who received capecitabine relative to a similar population of pediatric patients who participated in other clinical trials. The adverse reaction profile of capecitabine was consistent with the known adverse reaction profile in adults, with the exception of laboratory abnormalities which occurred more commonly in pediatric patients.

Medical management of 2000mg should include customary supportive medical interventions aimed at correcting the presenting clinical manifestations. Although no clinical experience using dialysis as a treatment for XELODA overdose has been reported, dialysis may be of benefit in reducing circulating concentrations of 5'-DFUR, a low— molecular-weight metabolite of the parent compound.

Hypersensitivity XELODA is contraindicated in patients with known hypersensitivity to capecitabine or to any of its components.